Merck bags global rights to NGM NASH drug, plans phase 2b trial

Merck has acquired the exclusive global rights to NGM Biopharmaceuticals’ treatment for NASH and Type 2 diabetes. The agreement gives Merck control of a drug designed to reduce liver fat content by selectively activating FGFR1c.